Supplements
What the Research Actually Says About What Supplements Affect Triglycerides?
Nearly one in three American adults has elevated triglycerides — yet most people focus exclusively on LDL cholesterol and miss this equally dangerous cardiovascular marker. The supplement aisle is full of bold claims, but only a handful of ingredients have rigorous clinical evidence behind them. Here is what the research actually shows.
What the Research Actually Says About What Supplements Affect Triglycerides?
Triglycerides are the most abundant fat molecules in your bloodstream, and they are not just a passive storage form of energy. Elevated fasting triglycerides — anything above 150 mg/dL, and especially above 200 mg/dL — are independently associated with increased risk of cardiovascular disease, insulin resistance, metabolic syndrome, and non-alcoholic fatty liver disease. What makes this marker particularly tricky is that a person's LDL can look perfectly normal while their triglycerides are silently elevated, especially after meals high in refined carbohydrates or alcohol.
So what actually moves this number? Below is an evidence-based breakdown of the supplements with the strongest clinical track records for lowering triglycerides, along with honest notes on dosing, effect size, and what the research limitations are.
---
Omega-3 Fatty Acids: The Most Documented Triglyceride-Lowering Supplement
If you only read one section of this article, make it this one. The evidence for high-dose omega-3 fatty acids — specifically EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) — reducing triglycerides is among the most replicated findings in nutritional medicine.
A landmark meta-analysis published in Atherosclerosis examined 68 randomized controlled trials and found that EPA and DHA supplementation significantly reduced fasting triglycerides by an average of 15–20% at doses of 2–4 grams per day (Musa-Veloso et al., Atherosclerosis 2010; PMID: 20537659). Effect sizes were dose-dependent: higher triglycerides at baseline produced larger absolute reductions.
The mechanism is well understood. Omega-3 fatty acids suppress hepatic VLDL synthesis (the lipoprotein particle that carries triglycerides into the blood), increase triglyceride clearance via lipoprotein lipase activity, and reduce de novo lipogenesis in the liver. They also activate PPAR-alpha, a nuclear receptor that upregulates fatty acid oxidation.
For people with very high triglycerides (above 500 mg/dL), prescription EPA-only formulations like icosapentaenoic acid have demonstrated reductions of 45% or more. For the general supplementation range, 2–4 grams of combined EPA + DHA daily is the clinically supported target — a dose that goes well beyond what most fish oil capsules deliver at the typical one-per-day serving.
| Omega-3 Dose | Expected TG Reduction | Evidence Quality |
|---|---|---|
| <1 g EPA+DHA/day | Minimal | Weak |
| 1–2 g EPA+DHA/day | 10–15% | Moderate |
| 2–4 g EPA+DHA/day | 15–30% | Strong (RCT level) |
| >4 g EPA+DHA/day | Up to 45% | Strong (Rx studies) |
---
Niacin (Vitamin B3): Powerful but Context-Dependent
Niacin at pharmacological doses (1,500–3,000 mg/day) is one of the most effective agents known to raise HDL cholesterol and lower triglycerides. Reductions of 20–50% in triglycerides have been documented in clinical settings (Kamanna & Kashyap, American Journal of Cardiology 2008; PMID: 18375237).
The mechanism involves niacin binding to GPR109A receptors in adipocytes, which acutely inhibits free fatty acid release from adipose tissue. This reduces the substrate supply for hepatic VLDL synthesis, which in turn lowers the triglycerides that get packaged into VLDL particles.
However, the context matters enormously. The AIM-HIGH and HPS2-THRIVE trials — two large cardiovascular outcome trials — found that adding extended-release niacin to statin therapy did not reduce cardiovascular events and actually increased adverse effects, including flushing, liver enzyme elevation, and new-onset diabetes (HPS2-THRIVE Collaborative Group, NEJM 2014; PMID: 24552320). This has significantly cooled enthusiasm for niacin as a standalone cardiovascular intervention.
The takeaway: niacin moves triglycerides meaningfully, but its risk-benefit ratio in the context of modern statin therapy is less favorable than once believed. It remains a tool worth discussing with your healthcare provider if you have severe hypertriglyceridemia.
---
Berberine: An Emerging Metabolic Regulator
Berberine, an alkaloid found in plants like Berberis aristata and goldenseal, has attracted considerable research attention for its effects on blood glucose, lipids, and insulin sensitivity. Several randomized controlled trials have examined its impact on the full lipid panel.
A meta-analysis of 27 RCTs involving 2,569 participants found that berberine supplementation significantly reduced triglycerides by an average of 0.50 mmol/L (approximately 44 mg/dL), along with meaningful reductions in total cholesterol and LDL (Lan et al., Journal of Ethnopharmacology 2015; PMID: 25498346). The typical dose used across these trials was 500 mg taken two to three times daily with meals.
Berberine's triglyceride-lowering effect appears to be mediated through AMPK activation — the same enzyme targeted by metformin. AMPK activation inhibits ACC (acetyl-CoA carboxylase), a rate-limiting enzyme in fatty acid synthesis, while simultaneously enhancing fatty acid oxidation. Berberine also upregulates LDL receptor expression, which explains its parallel LDL-lowering effect.
One important caveat: berberine inhibits CYP3A4 and P-glycoprotein, meaning it can interact with certain medications. Anyone on pharmaceuticals — especially statins, blood thinners, or blood sugar medications — should consult a healthcare provider before adding berberine.
---
Fiber (Soluble): A Foundational but Underrated Player
Soluble fiber — including psyllium husk, beta-glucan, and glucomannan — is most celebrated for its LDL-lowering effects through bile acid sequestration, but its impact on triglycerides is real and often overlooked.
Postprandial (after-meal) triglycerides are a particularly important cardiovascular risk factor, and soluble fiber slows gastric emptying, reduces the glycemic response to carbohydrates, and blunts the postprandial lipemic spike. A Cochrane systematic review of psyllium supplementation found modest but consistent reductions in triglycerides across multiple trials, most notable in people with metabolic syndrome or type 2 diabetes (Jovanovski et al., American Journal of Clinical Nutrition 2018; PMID: 29378044).
The practical implication: fiber should be a foundational dietary habit for anyone managing elevated triglycerides, not a replacement for targeted supplementation.
---
What Supplements Affect Fibrinogen?
Fibrinogen is a clotting protein synthesized in the liver, and elevated levels (above 400 mg/dL) are an independent cardiovascular risk factor — they signal systemic inflammation and increase thrombotic risk. While fibrinogen is not the same marker as triglycerides, they often co-elevate in metabolic syndrome and chronic inflammation, and several supplements influence both.
Omega-3 fatty acids, discussed above, also modestly reduce fibrinogen. A review published in Thrombosis Research found that EPA and DHA supplementation produced small but consistent reductions in plasma fibrinogen, likely through their anti-inflammatory effects on hepatic acute-phase protein production (Danesh et al., Circulation 1998; PMID: 9714141).
Nattokinase — a serine protease derived from fermented soybeans — has been studied for its direct fibrinolytic activity, meaning it breaks down fibrin clots and may lower circulating fibrinogen. While research is still early-stage compared to omega-3s, several small RCTs have shown promising effects on fibrinogen and blood viscosity. Similarly, curcumin has demonstrated anti-inflammatory properties that may secondarily reduce fibrinogen as part of its broader effect on CRP and inflammatory cytokines.
For people whose lab work shows both elevated triglycerides and elevated fibrinogen, addressing systemic inflammation through targeted anti-inflammatory support is often the more meaningful upstream intervention.
---
What About Supplements Marketed for Other Markers — Do They Affect Triglycerides?
This is where some important clarifications belong. Several secondary keywords attached to cardiovascular supplement research relate to thyroid function markers — specifically free T4, free T3, and TSH. These are hormone values, not lipid values, and the research on what supplements directly affect those markers is a separate domain from triglyceride metabolism. We will address those in dedicated articles on thyroid support supplements and lab markers.
The connection worth naming here: hypothyroidism and subclinical thyroid dysfunction are known to cause secondary dyslipidemia, including elevated triglycerides. If your triglycerides remain elevated despite diet, exercise, and supplementation, asking your provider to evaluate your thyroid panel — including TSH, free T4, and free T3 — is clinically appropriate. An underactive thyroid slows lipoprotein lipase activity, reduces LDL receptor expression, and impairs fatty acid oxidation, all of which drive triglyceride accumulation. Treating the thyroid dysfunction often improves the lipid panel significantly without additional lipid-specific interventions.
---
What This Means for Your Formula
Elevated triglycerides rarely exist in isolation. They typically appear alongside insulin resistance, low HDL, visceral adiposity, and systemic inflammation — a cluster that responds best to multi-mechanism support rather than a single ingredient.
At Ones, the AI health practitioner analyzes your blood work — including your fasting triglycerides, HDL, VLDL, fasting glucose, and inflammatory markers — alongside wearable data and health history to identify which mechanisms are most likely driving your specific pattern. Based on those findings, it calibrates a custom capsule formula from clinically validated ingredients.
For triglyceride-specific concerns, three ingredients from the Ones catalog are particularly relevant:
- Omega-3 (EPA/DHA): Included at therapeutic doses aligned with the 2–4 g/day range supported by meta-analysis data, not the token 300 mg doses found in most off-the-shelf fish oil capsules. This is the highest-evidence ingredient for fasting triglyceride reduction.
- Ones Heart Support (System Blend): A proprietary blend designed to address multiple cardiovascular risk pathways — including endothelial function, lipid metabolism, and oxidative stress — for individuals whose blood work flags broader cardiometabolic risk rather than isolated triglyceride elevation.
- CoQ10/Ubiquinol (200 mg): For individuals whose lipid panel includes markers of oxidative LDL modification or whose history includes statin use, CoQ10 at 200 mg addresses mitochondrial energy production and reduces LDL oxidation, a complementary mechanism to direct triglyceride lowering. Statin users deplete CoQ10 and frequently show both triglyceride elevation and energy complaints.
Because Ones formulas are calibrated to the individual's specific findings — not assembled from a generic template — someone with severe hypertriglyceridemia (>500 mg/dL) and metabolic syndrome would receive a meaningfully different formula than someone with borderline triglycerides driven primarily by refined carbohydrate intake and mild insulin resistance.
Always discuss significant lipid abnormalities with a licensed healthcare provider before relying solely on supplementation. Prescription interventions exist for a reason, and supplements work best as part of a comprehensive protocol.
---
Key Takeaways
- Omega-3 fatty acids (EPA + DHA) at 2–4 grams daily are the most robustly documented supplements for lowering fasting triglycerides, with effect sizes of 15–30% in RCTs.
- Berberine at 500 mg two to three times daily has demonstrated meaningful triglyceride reductions (~44 mg/dL average) across 27 RCTs, likely through AMPK activation.
- Niacin is potent but its cardiovascular risk-benefit ratio in people already on statins is unfavorable; use only under medical supervision.
- Soluble fiber blunts postprandial lipemia and should be treated as a foundational strategy, not an optional add-on.
- Elevated fibrinogen often co-occurs with high triglycerides in metabolic syndrome; omega-3s, nattokinase, and curcumin show promise for fibrinogen, though evidence is less mature.
- Subclinical hypothyroidism can cause secondary hypertriglyceridemia — if supplements and diet aren't moving your numbers, ask your provider to check TSH, free T4, and free T3.